文献速递系统性红斑狼疮

转录组分析揭示系统性红斑狼疮治疗应答的分子基础

Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus.
PubMed 文献 · RMD Open · 2025-03-12

研究对92例活动性SLE患者基线及治疗6个月后(32例配对样本)血液行RNA测序,治疗包括环磷酰胺40例、利妥昔单抗20例、贝利尤单抗23例、吗替麦考酚酯8例、硫唑嘌呤1例;应答以狼疮低疾病活动状态定义。应答者基线B细胞免疫及补体激活相关特征升高,有效治疗可逆转B细胞免疫特征;环磷酰胺独特下调中性粒细胞活化通路;539基因特征与治疗应答不足相关。

要点

  • 应答者基线B细胞免疫和补体激活相关转录特征升高,有效治疗可逆转B细胞免疫特征。
  • 利妥昔单抗对B细胞通路活性降低最显著,环磷酰胺独特下调中性粒细胞活化通路。
  • 539基因特征富集趋化因子信号过程,可区分治疗应答不足的患者。

核心结论

  • 基线B细胞免疫转录特征与有利治疗结局相关,可解释血清学活动患者应答更佳,有效治疗可逆转该特征。
  • 环磷酰胺独特靶向与重型SLE相关的中性粒细胞基因特征。
  • 趋化性改变可能是驱动SLE治疗抵抗的机制。

研究设计与样本

  • 对92例活动性SLE患者基线及治疗6个月后(32例配对样本)血液行RNA测序。
  • 治疗包括环磷酰胺40例、利妥昔单抗20例、贝利尤单抗23例、吗替麦考酚酯8例、硫唑嘌呤1例。
  • 应答以狼疮低疾病活动状态定义,识别差异表达基因与共表达转录模块。

主要发现

  • 无论何种治疗,达到应答均伴随B细胞免疫相关和补体激活相关特征的 downregulation。
  • 利妥昔单抗导致B细胞通路活性降低最显著,环磷酰胺独特下调中性粒细胞活化通路。
  • 应答者无论用药,治疗前中性粒细胞迁移、I型干扰素信号、补体激活和B细胞功能相关通路活性升高。
  • 539基因特征富集趋化因子信号相关过程,表征治疗应答不足的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment response and resistance in SLE. METHODS: Blood was collected from 92 active patients with SLE at baseline and after 6 months (n=32 paired samples) of treatment with cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) and was subjected to RNA sequencing. The response was defined by the Lupus Low Disease Activity State. We identified differentially expressed genes and co-expressed transcript modules. RESULTS: Achieving response, irrespective of treatment, was accompanied by downregulation of B cell immunity-related and complement activation-related signatures. Rituximab led to the most profound decrease in the activity of the B cell pathway, while cyclophosphamide uniquely downregulated neutrophil activation pathways. Responders, regardless of medication, showed increased activity in pathways related to neutrophil migration, type I interferon signalling, complement activation and B cell function prior to treatment. A 539-gene signature, enriched in processes related to chemokine signalling, characterised patients with insufficient response to treatment. CONCLUSIONS: Baseline B cell immunity transcriptional signatures correlate with favourable treatment outcomes-accounting for better responses in serologically active patients in SLE clinical trials-with effective treatment reversing the B cell immunity signature. Cyclophosphamide uniquely targets a neutrophil gene signature linked to severe SLE. Alterations in chemotaxis may represent a mechanism driving resistance to treatment in SLE.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Garantziotis P, Moysidou GS, Kapsala N, et al. Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus. RMD Open. 2025. PMID: 40081913. doi:10.1136/rmdopen-2024-005050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。